Malignant Reproductive System Neoplasm — Research

Malignant Reproductive System Neoplasm — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-11	39	`("Malignant Reproductive System Neoplasm"[tiab] OR "Reproductive System Cancer"[tiab] OR "Cancer of Reproductive System"[tiab] OR "Cancer of the Reproductive System"[tiab])`	2026-09-11	pubmed
Last 5 years	2021-01-01 → 2026-12-31	21	`("Malignant Reproductive System Neoplasm"[tiab] OR "Reproductive System Cancer"[tiab] OR "Cancer of Reproductive System"[tiab] OR "Cancer of the Reproductive System"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-11	pubmed
Last 12 months	2025-09-11 → 2026-09-11	3	`("Malignant Reproductive System Neoplasm"[tiab] OR "Reproductive System Cancer"[tiab] OR "Cancer of Reproductive System"[tiab] OR "Cancer of the Reproductive System"[tiab]) AND (2025/09/11:2026/09/11[dp])`	2026-09-11	pubmed

Data updated 20 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (605)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 526–550 of 605 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.
· Invest New Drugs · 2015 · PMID 26490654 · validated civic_curation pubmed
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.
· JCO Precis Oncol · 2024 · PMID 38603650 · validated civic_curation pubmed
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
· Clin Cancer Res · 2015 · PMID 25370471 · validated civic_curation pubmed
A practical approach to aid physician interpretation of clinically actionable predictive biomarker results in a multi-platform tumor profiling service.